New Products & Services

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.